Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biological roles. Until now, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms. Recently published patent specifications describe new PI3K inhibitors, including several that are selective for the PI3Kdelta isoform. There is now cautious optimism that isoform-selective PI3K inhibitors will provide new avenues for therapeutic applications in a range of diseases.
Ward
Stephen G
SG
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. S.G.Ward@bath.ac.uk
Finan
Peter
P
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002465:Cell Movement / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000276:immunology; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D018417:Th1 Cells / Q000201:enzymology; D018418:Th2 Cells / Q000201:enzymology
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors